Regeneron rises after rare immune disorder therapy improves daily functions in trial

** Shares of drugmaker Regeneron Pharmaceuticals REGN.O up 2.1% at $584.39

** REGN says its experimental therapy, cemdisiran, met the late-stage main goal of helping patients with a rare immune disorder and significantly improved their daily functions, such as talking and eating

** Cemdisiran was being tested in adults with generalized myasthenia gravis, a condition where the body attacks itself, weakening the skeletal muscles, especially those controlling the eyes, mouth, throat and limbs

** Company plans to submit a marketing application in early 2026 with the U.S. FDA

** "Cemdisiran showed best-in-class results on the MG-ADL scale, with the added benefit of quarterly subcutaneous dosing that offers better and more consistent coverage than current IV or FcRN-based treatments" - TD Cowen

** Including session moves, REGN down 18.2% YTD